Skip to main content
. 2022 Nov 3;16:1464. doi: 10.3332/ecancer.2022.1464

Table 4. Table depicting the site, intent, lines of treatment and drugs used.

Site Intent Line of treatment Drugs
Head and neck Palliative 1st line, 2nd line and beyond Nivolumab
Pembrolizumab
NSCLC Palliative 1st line, 2nd line and beyond Nivolumab
Nivolumab + Ipilimumab
Pembrolizumab
Atezolizumab
NSCLC Curative - Durvalumab
SCLC Palliative 1st line Atezolizumab
Oesophagus Palliative 2nd line and beyond Nivolumab

NSCLC, Non-small cell lung cancer; SCLC, Small cell lung cancer